201 related articles for article (PubMed ID: 30053166)
1. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register.
Macfarlane GJ; MacDonald RIR; Pathan E; Siebert S; Gaffney K; Choy E; Packham J; Martin KR; Haywood K; Sengupta R; Atzeni F; Jones GT
Rheumatology (Oxford); 2018 Nov; 57(11):1982-1990. PubMed ID: 30053166
[TBL] [Abstract][Full Text] [Related]
2. The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis.
Provan SA; Dean LE; Jones GT; Macfarlane GJ
Rheumatology (Oxford); 2021 Sep; 60(9):4121-4129. PubMed ID: 34469570
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study.
Moltó A; Etcheto A; Gossec L; Boudersa N; Claudepierre P; Roux N; Lemeunier L; Martin A; Sparsa L; Coquerelle P; Soubrier M; Perrot S; Dougados M
Ann Rheum Dis; 2018 Apr; 77(4):533-540. PubMed ID: 29183878
[TBL] [Abstract][Full Text] [Related]
4. Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register.
Macfarlane GJ; Barnish MS; Pathan E; Martin KR; Haywood KL; Siebert S; Packham J; Atzeni F; Jones GT
Arthritis Rheumatol; 2017 Nov; 69(11):2144-2150. PubMed ID: 28622461
[TBL] [Abstract][Full Text] [Related]
5. Fibromyalgia in Spondyloarthritis: Effect on Disease Activity Assessment in Clinical Practice.
Wach J; Letroublon MC; Coury F; Tebib JG
J Rheumatol; 2016 Nov; 43(11):2056-2063. PubMed ID: 27633820
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis.
Bello N; Etcheto A; Béal C; Dougados M; Moltó A
Arthritis Res Ther; 2016 Feb; 18():42. PubMed ID: 26860612
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis.
Santos-Faria D; Dougados M; Gossec L; Perrot S; Moltó A
Rheumatol Int; 2019 Jan; 39(1):141-146. PubMed ID: 30413924
[TBL] [Abstract][Full Text] [Related]
8. Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies.
Zhao SS; Yoshida K; Jones GT; Hughes DM; Tedeschi SK; Lyu H; Moots RJ; Solomon DH; Goodson NJ
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):591-599. PubMed ID: 30762311
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?
Jones GT; Dean LE; Pathan E; Hollick RJ; Macfarlane GJ
Ann Rheum Dis; 2020 Jul; 79(7):914-919. PubMed ID: 32327428
[TBL] [Abstract][Full Text] [Related]
10. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis.
Krabbe S; Glintborg B; Østergaard M; Hetland ML
Scand J Rheumatol; 2019 Mar; 48(2):128-132. PubMed ID: 30102111
[TBL] [Abstract][Full Text] [Related]
11. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
12. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
13. Role of Metrology in Axial Spondyloarthritis: Does It Provide Unique Information in Assessing Patients and Predicting Outcome? Results From the British Society for Rheumatology Biologic Register for Ankylosing Spondylitis.
Biallas RL; Dean LE; Davidson L; Hollick R; Pathan E; Robertson L; Jones GT; Macfarlane GJ; Rotariu O
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):665-674. PubMed ID: 33140891
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
[TBL] [Abstract][Full Text] [Related]
15. Fibromyalgia in Spondyloarthritis: Prevalence and Effect on Disease Activity and Treatment.
Olfa S; Bouden S; Sahli M; Tekaya AB; Rouached L; Rawdha T; Mahmoud I; Abdelmoula L
Curr Rheumatol Rev; 2023; 19(2):214-221. PubMed ID: 36056847
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS.
Zhao SS; Jones GT; Macfarlane GJ; Hughes DM; Moots RJ; Goodson NJ
Rheumatology (Oxford); 2021 Sep; 60(9):4158-4165. PubMed ID: 33369676
[TBL] [Abstract][Full Text] [Related]
17. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
18. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
19. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
[TBL] [Abstract][Full Text] [Related]
20. Tender to touch-Prevalence and impact of concomitant fibromyalgia and enthesitis in spondyloarthritis: An ancillary analysis of the ASAS PerSpA study.
Fitzgerald GE; Maguire S; Lopez-Medina C; Dougados M; O'Shea FD; Haroon N
Joint Bone Spine; 2022 Nov; 89(6):105420. PubMed ID: 35636706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
